Repligen Corporation (RGEN) reported quarterly earnings results on Thursday, Aug-4-2016. The company said it had a profit of $0.16 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.03. Analysts had a consensus of $0.13. The company posted revenue of $29.20 million in the period, compared to analysts expectations of $24.85 million. The company’s revenue was up 35.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.11 EPS.
Repligen Corporation closed down -0.17 points or -0.57% at $29.7 with 3,69,233 shares getting traded on Tusday. Post opening the session at $29.81, the shares hit an intraday low of $29.33 and an intraday high of $30.06 and the price fluctuated in this range throughout the day.Shares ended Tusday session in Red.
In a different news, on Jul 1, 2016, Thomas F Jr Ryan (director) sold 5,000 shares at $26.60 per share price. According to the SEC, on May 19, 2015, James R Rusche (Senior Vice President) sold 15,000 shares at $41.32 per share price. On May 14, 2015, Walter C Herlihy (PRESIDENT, CEO) sold 45,431 shares at $38.97 per share price, according to the Form-4 filing with the securities and exchange commission.
Repligen Corporation (Repligen) is a life sciences company. The Company develops manufactures and markets bioprocessing products for life sciences and biopharmaceutical companies across the world. The Company is a manufacturer of both native and recombinant forms of Protein A critical reagents used in biomanufacturing to purify monoclonal antibodies which is a type of biologic drug. It also supplies several growth factor products and cell filtration products used to increase cell culture productivity during the bioproduction process. It has developed a series of OPUS chromatography columns for use in clinical-scale manufacturing. It manufactures and sells Protein A and growth factors to life sciences companies under supply agreements and sells chromatography columns as well as media and quality test kits and the Company’s Alternating Tangential Flow (ATF) products directly to biopharmaceutical companies or contract manufacturing organizations or through distributors.